Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, T-Cell

Explore clinical trials studying Lymphoma, T-Cell. Study availability and eligibility vary by location and protocol.

694 public trials 105 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, T-Cell trial results

Completed

Romidepsin and Lenalidomide in Treating Patients With Previously Untreated Peripheral T-Cell Lymphoma

NCT02232516

Conditions
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, +32 more
Locations
  • City of Hope Duarte, California, United States
  • Yale University New Haven, Connecticut, United States
  • Northwestern University Chicago, Illinois, United States
  • Weill Cornell Medicine New York, United States
View Trial Details
Completed

Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma

NCT06113081

Conditions
Cutaneous T Cell Lymphoma, Cutaneous T-Cell Lymphoma/Mycosis Fungoides, Cutaneous T-Cell Lymphoma/Sezary Syndrome, +17 more
Locations
  • Clinica di Ematologia - AOU Ospedali Riuniti delle Marche Ancona, Italy
  • S.C. Ematologia e Trapianto emopoietico - A.O. S.Giuseppe Moscati Avellino, Italy
  • Clinica Dermatologia - A.O.U. Policlinico Consorziale Bari, Italy
  • U.O.C. Ematologia - IRCCS Istituto Tumori Giovanni Paolo II Bari, Italy
View all 21 locations
View Trial Details
Completed

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

NCT02362997

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Hodgkin Disease, +14 more
Locations
  • City of Hope National Medical Center Duarte, California, United States
  • Massachusetts General Hospital Boston, Massachusetts, United States
  • Beth Israel Deaconess Medical Center Boston, Massachusetts, United States
  • Dana Farber Cancer Institute Boston, Massachusetts, United States
View Trial Details
Completed

Nivolumab and the Antagonistic CSF-1R Monoclonal Antibody Cabiralizumab (BMS-986227) in Patients With Relapsed/Refractory Peripheral T Cell Lymphoma

NCT03927105

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Michigan Comprehensive Cancer Center Ann Arbor, Michigan, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • Unviersity of Wisconsin Madison, Wisconsin, United States
View Trial Details
Completed

Romidepsin, Gemcitabine, Dexamethasone and Cisplatin in the Treatment of Peripheral T-Cell and Diffuse Large B-Cell Lymphoma

NCT01846390

Conditions
Diffuse Large B-cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +12 more
Locations
  • Tom Baker Cancer Centre Calgary, Alberta, Canada
  • BCCA - Vancouver Cancer Centre Vancouver, British Columbia, Canada
  • Regional Health Authority B, Zone 2 Saint John, New Brunswick, Canada
  • QEII Health Sciences Centre Halifax, Nova Scotia, Canada
View Trial Details
Completed

A Study of Brentuximab Vedotin and CHP in Frontline Treatment of PTCL With Less Than 10% CD30 Expression

NCT04569032

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • University of Alabama at Birmingham Birmingham, Alabama, United States
  • Stanford Cancer Center Stanford, California, United States
  • Stanford Hospital and Clinics, Investigational Drug Services Stanford, California, United States
View all 63 locations
View Trial Details

Related conditions